Skip to content

A FIH Trial of the STREAMLINE™ SURGICAL SYSTEM

A First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the STREAMLINE™ SURGICAL SYSTEM in Patients With Open-Angle Glaucoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04700189
Enrollment
42
Registered
2021-01-07
Start date
2020-12-04
Completion date
2022-09-21
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular Pressure, Open Angle Glaucoma

Keywords

Intraocular Pressure, Glaucoma, Glaucoma Surgery, Ab interno

Brief summary

The purpose of this study is to evaluate the safety and Intraocular pressure lowering effectiveness of the Streamline™ Surgical System.

Detailed description

This is a prospective, nonrandomized, open-label study evaluating the safety and IOP-lowering effectiveness of CPI Visco-Surgical System (STREAMLINE™ SURGICAL SYSTEM) in patients with open-angle glaucoma undergoing cataract surgery.

Interventions

DEVICEab interno canaloplasty

A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.

Sponsors

New World Medical, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects must meet all the following criteria in order to be eligible for participation in this study: 1. Subjects qualifying for cataract surgery 2. Subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated IOP of 21-36 mmHg.

Exclusion criteria

* Subjects are ineligible for participation in this study if s/he meets any of the following criteria: 1. Patients who could not be washed-out of IOP-lowering medications. .

Design outcomes

Primary

MeasureTime frameDescription
Proportion of unmedicated eyes with intraocular pressure (IOP) reduction of ≥20%From Baseline at Month 12Descriptive

Secondary

MeasureTime frameDescription
Changes from baseline in intraocular pressure (IOP)From Baseline at Month 12Exploratory analysis
Changes from baseline in number of IOP lowering medicationsFrom Baseline at Month 12Exploratory analysis

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026